Disease Dynamics Unit, Department of Veterinary Medicine, University of Cambridge, Cambridge, UK.
Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
Vaccine. 2019 Sep 3;37(37):5657-5663. doi: 10.1016/j.vaccine.2017.12.069. Epub 2018 Jan 20.
Streptococcus pneumoniae is increasingly recognised as an important cause of bacterial meningitis in the African meningitis belt. The World Health Organization sets guidelines for response to outbreaks of meningococcal meningitis, but there are no current guidelines for outbreaks where S. pneumoniae is implicated. We aimed to evaluate the impact of using a similar response to target outbreaks of vaccine-preventable pneumococcal meningitis in the meningitis belt. Here, we adapt a previous model of reactive vaccination for meningococcal outbreaks to estimate the potential impact of reactive vaccination in a recent pneumococcal meningitis outbreak in the Brong-Ahafo region of central Ghana using weekly line list data on all suspected cases over a period of five months. We determine the sensitivity and specificity of various epidemic thresholds and model the cases and deaths averted by reactive vaccination. An epidemic threshold of 10 suspected cases per 100,000 population per week performed the best, predicting large outbreaks with 100% sensitivity and more than 85% specificity. In this outbreak, reactive vaccination would have prevented a lower number of cases per individual vaccinated (approximately 15,300 doses per case averted) than previously estimated for meningococcal outbreaks. Since the burden of death and disability from pneumococcal meningitis is higher than that from meningococcal meningitis, there may still be merit in considering reactive vaccination for outbreaks of pneumococcal meningitis. More outbreak data are needed to refine our model estimates. Whatever policy is followed, we emphasize the importance of timely laboratory confirmation of suspected cases to enable appropriate decisions about outbreak response.
肺炎链球菌越来越被认为是非洲脑膜炎带细菌性脑膜炎的重要病因。世界卫生组织为应对脑膜炎奈瑟菌脑膜炎的暴发制定了应对指南,但对于涉及肺炎链球菌的暴发,目前尚无相关指南。我们旨在评估针对疫苗可预防的肺炎球菌性脑膜炎暴发采取类似应对措施的效果,以评估在加纳中部布隆-阿哈福地区最近发生的肺炎球菌性脑膜炎暴发中使用这种反应性疫苗接种的潜在影响。在此,我们采用先前针对脑膜炎奈瑟菌暴发的反应性疫苗接种模型,使用五个月期间每周所有疑似病例的列表数据,对布隆-阿哈福地区最近发生的肺炎球菌性脑膜炎暴发进行了模拟。我们确定了各种流行阈值的敏感性和特异性,并对反应性疫苗接种可预防的病例和死亡人数进行了建模。每周每 10 万人中有 10 例疑似病例的流行阈值表现最佳,可 100%敏感地预测出大型暴发,特异性超过 85%。在此次暴发中,反应性疫苗接种可能会预防每例个体接种的病例数量减少(大约每例可预防 15300 剂),低于之前对脑膜炎奈瑟菌暴发的估计。由于肺炎球菌性脑膜炎的死亡和残疾负担高于脑膜炎奈瑟菌脑膜炎,因此针对肺炎球菌性脑膜炎暴发考虑反应性疫苗接种仍可能具有一定意义。需要更多的暴发数据来完善我们的模型估计。无论遵循哪种政策,我们都强调及时确认疑似病例的重要性,以便能够做出适当的暴发应对决策。